Comments
HCG has entered into a joint venture with Cvergenx to develop, validate and launch precision genomic radiation therapy (pGRTTM) technology in India and Africa.
This joint venture will be an exclusive vehicle through which this technology will be made available in those countries, HCG said in a statement.
Further, the proprietary pGRTTM platform, developed at Cvergenx by doctor Javier Torres-Roca, co-founder and Director, Clinical Research, Department of Radiation Oncology, Moffitt Cancer Center and Research Institute, is the first clinically validated approach to guide radiation dosage based upon the Radiosensitivity Index (RSI) of patients, company executives said. This joint venture will be one of the first initiatives to validate and bring into clinical practice a solution that integrates genomics into radiation treatment planning and therapy in India. “This technology will allow oncologists to precisely decide radiation treatment for cancer patients based on their genomic profile and has the potential to truly revolutionize cancer care” said B.S. Ajaikumar, Chairman and CEO of HCG.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.